rs7850258 — PTCSC2

The FOXE1 Enhancer Switch That Sets Your Thyroid's Developmental Tone

About 67.7 kilobases upstream of the FOXE1 gene — a master regulator of thyroid gland formation — sits a conserved enhancer element that fine-tunes how much FOXE1 protein the developing and adult thyroid produces. The rs7850258 variant sits inside this enhancer and changes which transcription factors can bind there. The result is a meaningful shift in thyroid development trajectory and lifetime hypothyroidism risk, embedded in the 9q22.33 thyroid disease locus¹¹ the 9q22.33 thyroid disease locus
One of the most replicated genetic regions in thyroid medicine, containing multiple independent signals for thyroid cancer, hypothyroidism, and TSH levels.

The Mechanism

FOXE1²² FOXE1
Forkhead Box E1, also known as thyroid transcription factor 2 (TTF-2) is essential for thyroid morphogenesis — mice lacking FOXE1 fail to form a thyroid gland. In adults, FOXE1 maintains the differentiated state of thyroid follicular cells. The rs7850258 variant determines whether a specific E-box sequence in the upstream enhancer is active or dormant.

The G allele creates a functional E-box motif that recruits MYC and ARNT transcription factors³³ MYC and ARNT transcription factors
Two bHLH proteins that bind E-box (CACGTG) sequences; their binding is 1.2–1.7-fold stronger at the G allele than the A allele in luciferase reporter assays. This stronger binding drives greater enhancer activity, pushing FOXE1 expression higher during thyroid development. Counter-intuitively, higher embryonic FOXE1 expression appears to disrupt normal thyroid morphogenesis rather than enhance it — possibly by inducing apoptosis or altering the timing of follicular cell differentiation — resulting in a thyroid gland with subtly reduced functional reserve in G-allele carriers. The A allele, by contrast, lacks strong E-box binding and is associated with reduced FOXE1 enhancer output, which (by a separate mechanism) creates a permissive environment for thyroid tumour development.

This creates the unusual situation where the G allele raises hypothyroidism risk while the A allele raises thyroid cancer risk — the same locus pushes the thyroid toward different pathological endpoints depending on the direction of FOXE1 dysregulation.

The Evidence

The discovery study by Denny et al. 2011⁴⁴ Denny et al. 2011
American Journal of Human Genetics, 1,317 hypothyroidism cases + 5,053 controls, replication in 263 + 1,616 controls identified rs7850258 as the strongest GWAS signal for hypothyroidism at the 9q22 locus (OR 1.35 per G allele, p = 3.96 × 10⁻⁹ under an additive model). The same variant also reached significance for thyroiditis (OR per G ~1.72), nodular goiter, and thyrotoxicosis, establishing it as a broad thyroid-function modulator. The A allele was present at 34.8% in controls versus only 28.5% in hypothyroidism cases, confirming the protective direction.

The functional mechanism was established by Lidral et al. 2015⁵⁵ Lidral et al. 2015
Human Molecular Genetics, multi-tissue enhancer assays in oral epithelial and thyroid cell lines. The G allele showed 1.2- to 1.7-fold greater enhancer activity across multiple cell types compared to the A allele. Transcription factor binding assays confirmed the G allele E-box recruits MYC and ARNT — proteins absent from the A-allele binding profile — providing a mechanistic explanation for the epidemiological associations.

Large-scale replication came from Mathieu et al. 2022⁶⁶ Mathieu et al. 2022
iScience, 51,194 hypothyroidism cases and 443,383 controls, which identified 139 hypothyroidism risk loci and confirmed rs7850258 as a genome-wide significant signal (beta = −0.212 per protective A allele). The Verma et al. 2024 multi-ancestry GWAS⁷⁷ Verma et al. 2024 multi-ancestry GWAS
Science, ~636,000 participants across ancestries further confirmed the association with thyroid medication use (a proxy for hypothyroidism requiring treatment) at p = 2 × 10⁻¹¹⁹ — one of the most replicated endocrine GWAS signals outside of the major histocompatibility complex.

Practical Actions

For GG carriers (~52% of the population), the approximately 80% increased hypothyroidism risk compared to AA carriers justifies proactive TSH monitoring starting earlier than standard population guidelines. Current screening guidelines in many countries suggest TSH testing beginning at age 35–40; GG carriers have grounds to begin at 25–30 and repeat every 3–5 years. When TSH is borderline-high but still within the laboratory reference range (the so-called "high-normal" TSH between 2.5–4.5 mIU/L), additional context from a geneticist or endocrinologist is warranted before dismissing it as normal.

For individuals already diagnosed with hypothyroidism or subclinical hypothyroidism, this genotype helps explain the underlying susceptibility and does not change standard treatment decisions. However, when combined with the DIO2 Thr92Ala variant (rs225014), the combination of impaired thyroid functional reserve (this SNP) and impaired T4-to-T3 conversion (DIO2) may produce more pronounced symptoms at borderline thyroid function levels — a context where early treatment initiation may be warranted.

Interactions

rs7850258 lies approximately 7 kb from rs965513 — the strongest papillary thyroid cancer GWAS locus at 9q22.33. These two variants are in or near the same LD block and may represent partially overlapping genetic signals at the PTCSC2/ FOXE1 regulatory region. The allele directions are complementary: G at rs7850258 (hypothyroidism risk) tends to co-occur with the G allele at rs965513 (which is protective for thyroid cancer), creating an inverse relationship between hypothyroidism and thyroid cancer risk at this locus.

The variant also sits within the same functional genomic region studied for rs1867277 (FOXE1 5' UTR) and rs944289 (14q13.3), which are independent thyroid cancer risk loci. These variants operate through distinct regulatory mechanisms but all converge on FOXE1 expression regulation.

Compound implication for rs7850258-GG + DIO2 rs225014-CC: Individuals carrying both the hypothyroidism-risk GG genotype at rs7850258 and two copies of the DIO2 Thr92Ala variant may experience compound thyroid function challenges — reduced thyroid gland functional reserve combined with impaired peripheral T4-to-T3 conversion. If you have this combination and are on levothyroxine, discuss free T3 monitoring and possible combination T4/T3 therapy with your endocrinologist.